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Marked reduction of Tamm-HorsfaU protein synthesis in hyperpros-
taglandin E-syndrome. Hyperprostaglandin E-syndrome (HPS), a re-
cently described variant of Bartter's syndrome (BS), resembles BS in a
number of symptoms but is distinct from BS in others. Similar to BS,
HPS is characterized by congenital hypokalemic alkalosis, hypertrophy
of the juxtaglomerular apparatus, hyperreninemia, secondary hyperal-
dosteronism, normal blood pressure and renal diabetes insipidus. Other
than BS, HPS is constantly associated with chronic hypercalciuria and
nephrocalcinosis as well as both renal and systemic POE2 overproduc-
tion. Correction of most of the symptoms in HPS is achieved by
permanent inhibition of prostaglandin synthesis with indomethacin.
Among the causes leading to HPS, a selective damage of the distal
tubule in HPS has been suggested. Therefore, synthesis of Tamm-
Horsfall protein (THP), a glycoprotein exclusively produced in the
thick ascending limb of the loop of Henle, was measured by ELISA in
the urine of seven infant HPS patients (aged 3 to 8 years). Patients were
investigated both under constant indomethacin treatment and after a
one week period without indomethacin. Nine healthy children (aged 5
months to 10 years) served as controls. In controls mean daily THP
excretion was 54.2 13.9 (median 46.0) mg/24 hr/l .73 m2 whereas in
HPS, THP levels were strongly diminished. During withdrawal of
indomethacin treatment, mean THP level was 12.7 10.1 (median 7.2)
mg/24 hr/1.73 m2 and 10.3 10.1 (median 3.5) mg/24 hr/i .73 m2 under
indomethacin treatment, respectively. THP excretion values both with-
out indomethacin and under indomethacin treatment were significantly
different from controls (P  0.005); however, there was no significant
difference between the THP levels during or after cessation of indo-
methacin treatment. Creatinine clearance in HPS patients was 75.1
15.9 (median 76.2) ml/minll .73 m2 without indomethacin and 81.9
15.1 (median 83.0) mI/mm/I .73 m2 under indomethacin treatment,
Control values were not obtained. Comparative measurements of THP
excretion in six classical BS-patients (aged 3 months to 17 years)
revealed normal THP values in two individuals and intermediate levels
in the others: the mean level of six BS patients was 30.8 13.5 (median
25.0) mg124 hr/1.73 m2 and was thus significantly higher than in HPS
both with and without indomethacin treatment (P 0.05). Immunohis-
tochemistry in renal biopsies of three of the HPS patients showed a
strong reduction of cortical tubular THP immunoreactivity in two cases
and a less pronounced reduction in the third. In situ hybridization using
a THP-riboprobe in these three biopsies revealed significantly reduced
or absent THP-mRNA levels. The severely decreased THP-production
supports previous assumptions that one of the major causes underlying
HPS is a selective congenital defect of the distal tubule. Differences in
THP excretion between HPS and BS support a concept that defines
HPS and BS as separate entities with a number of similarities,
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Hyperprostaglandin E-syndrome (HPS), a congenital hy-
pokalemic tubular disorder, shares a number of basic features
with Bartter's syndrome (BS) [1, 2], but reveals several clinical
and pathophysiological differences from BS [3—5]. Similar to
BS, HPS is characterized by congenital hypokalemic alkalosis,
hypertrophy of the juxtaglomerular apparatus, hyperreninemia,
secondary hyperaldosteronism, normal blood pressure and re-
nal diabetes insipidus [4—6]. Unlike BS, in HPS both renal and
systemic prostaglandin E2-production are markedly stimulated,
distal chloride reabsorption is not altered [4], and chronic
hypercalciuria is established [3]. Polyhydramnion and prema-
ture birth indicate a prenatal onset of this syndrome. Additional
prostaglandin-mediated systemic complications like osteope-
nia, fever, secretory diarrhea and an increased susceptibility to
infection are present in HPS. Correction of most symptoms is
achieved by a constant indomethacin treatment [4, 6].
Striking similarities between HPS symptoms and chronic
furosemide intake (such as, sodium wasting, renal diabetes
insipidus, loss of potassium and enhanced calciuresis) [7],
indicate a selective defect of the distal tubule. Since Tamm-
Horsfall protein (THP) is thought to be related to the function of
the thick ascending limb of the ioop of Henle [8—11], the present
study was undertaken to investigate THP synthesis in HPS.
THP is the most abundant protein in normal urine with a daily
excretion rate of 50 to 100 mg/24 hr [12]. It is synthesized
exclusively by the epithelial cells of the thick ascending limb
with exception of the macula densa [10, 11, 13]. Though its
physiological role has not yet been understood, THP location in
the thick ascending limb suggests that this glycoprotein might
be involved in sodium or chloride transport [14—16] or in
maintaining the low water permeability of the thick ascending
limb [9]. Other hypothetical roles of THP concern the preven-
tion of bacterial adhesion along the urinary tract [17], an
immunoregulatory function due to its influence on the biological
activity of cytokines [18], as well as an involvement in the
prevention of renal calcium oxalate stones [19].
This paper reports urinary THP levels measured by ELISA in
infants with HPS and BS respectively, as well as in healthy
infant controls. Immunohistochemistry and in situ hybridiza-
tion histochemistry were used to show the distribution and
production of THP in renal biopsies of three of the HPS
patients.
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Table la. Laboratory parameters from patients with hyperprostaglandin E-syndrome
Urinary
Patients Sex
Age
years months
Gestation
weeks Polyhydramion
Indomethacin
treatment
THP
rng/24 hr/i .73 m2
HPS 1 male 4.7/12 36 yes yes 14.96
BPS 1 no 21.88
HPS 2 female 6.3/12 27 yes yes 0.91
HPS2 no 2.71
HPS 3 female 3.5/12 32 yes yes 3.02
HPS3 no 7.15
HPS 4 female 7.0/12 28 yes yes 3.50
BPS 4 no 6.55
BPS 5 female 7,5/12 33 yes yes 3.45
HPS 5 no 2.59
HPS 6 male 5.1/12 27 yes yes 15.00
HPS 6 no 17.29
HPS 7 male 7.4/12 30 yes yes 31.30
HPS 7 no 30.89
Mean = 5.10/12
SD = 1.5/12
Median = 6.3/12
Mean = 30.4
sn = 3.2
Median = 30.0
yes Mean = 10.31
SD = 10.14
Median = 3.50
Mean = 5.10/12
SD = 1.5/12
Median = 6.3/12
no Mean = 12.72
SD = 10.05
Median = 7.15
Normal range 37 to 42 50 to 100
Methods
Patients with hyperprostaglandin E-syndrome
Three male and four female HPS patients (aged 3 to 8 years,
mean 5.10/12 years) were investigated. HPS was diagnosed
based on polyhydramnion, premature birth (mean 30.4 weeks),
elevated urinary PGE2 and PGE-M levels, and hypercalciuria
with nephrocalcinosis. Patient history showed a maternal his-
tory of frequent spontaneous abortions in five cases. THP in
HPS patients was measured under constant indomethacin treat-
ment and after a one week period without indomethacin. Renal
biopsies of three of the HPS patients were available (Prof.
Waldherr, Heidelberg, Germany). Biopsies had been performed
approximately three years before the present investigation of
urinary parameters and had since been stored at —70°C. Urine
was stored at —20°C.
Patients with Bartter's syndrome
For comparison of THP levels, the urine of six patients
diagnosed with classical BS was studied. These patients (aged 3
months to 17 years, mean 10.10/12 years; five males, one
female) showed the typical clinical symptoms of BS such as
hypokalemia, metabolic alkalosis, hyperreninemia and second-
ary hyperaldosteronism.
Controls
Urine of nine healthy children (aged 5 months to 10 years,
mean 6.1/12; 4 males and 5 females) was also analyzed. These
children had no history of hypertension, diabetes, or urinary
tract infection. Urine was screened and found negative for
nitrite, proteins, glucose, ketone bodies, urobiinogen, biliru-
bin, blood and hemoglobin by Combur 8-Test©. Urinary pH
was within normal range.
Urine collection
Twenty-four hour urine collections were performed using
PVC containers suitable for collection of THP [20]. Urine was
stored at 4°C during the collection procedure and subsequently
frozen in aliquots of five ml and stored at —20°C. Samples from
foreign hospitals were collected correspondingly and sent in
frozen CO2. Urinary creatinine was used to control the correct-
ness of collection; 24 hour creatinine excretion per kilogram
body weight was considered to be relatively constant, that is to
vary slightly with alimentation, activity and diuresis. There was
no significant difference in creatinine values between the
groups.
Quantification of urinary THP by ELISA
Urinary THP was isolated by repeated precipitation from
pooled normal human urine with 0.58 M NaCI according to the
method of Tamm and Horsfall (1950) [211. Purity of the isolated
standard was established by SDS-polyacrylamide gel electro-
phoresis using a gradient of 4 to 12% (wt/vol). Gels were stained
with Coomassie blue. Immunoblotting was performed by trans-
fer to a blot membrane (Immobilon, Millipore, Eschborn,
Germany) which was subsequently incubated with monoclonal
mouse-anti-human THP antibody (Cedarlane Lab., Hornby,
Canada), dilution 1/1000 wt/vol in phosphate buffered saline
with 1/500 vol/vol Tween 20 (Merck, MUnchen, Germany)
[PBST]. For detection, an alkaline phosphatase-conjugated
anti-mouse antibody (Amersham, Braunschweig, Germany; di-
lution 1/500 vol/vol in PBST) was used. Both SDS-gel electro-
phoresis and Western blot showed a single band at approxi-
mately 90 kilodalton. For measuring THP in urine, an ELISA
was established with the first antibody bound to the solid phase
(monoclonal mouse-anti-human THP, Cedarlane Lab., Hornby,
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Table la. Continued
Urinary
Diuresis Osmolality Urinary Ca POE2 Urinary PGE-M CCR
mi/24 hr mOsmoi/kg moi/24 hr/kg ng/hr/I.73 m2 ng/hr/1.73 m2 mi/mini] .73 m2
700 237 49.6 1.3 31.7 83.0
2640 157 238.3 171.3 123.3 88.0
2040 207 80.3 ND 89.2 56.8
3480 120 285.6 137.1 465.0 44.6
880 266 97.5 36.1 247.3 103.0
2300 165 128.1 110.8 ND 71.4
2000 252 120.8 9.4 80.5 67.2
2580 153 357.7 66.3 483.1 76.2
883 293 148.1 5.6 234.5 78.0
1450 155 203.4 101.6 490.3 65.0
1310 346 132.9 1.5 59.4 87.0
2500 422 490.6 189.8 731.6 83.4
1800 272 141.4 ND 57.1 98.0
3400 135 326.0 81.3 554.9 97.0
Mean = 1373 Mean = 268 Mean = 110.1 Mean = 10.8 Mean = 114.3 Mean = 81.9
SD = 529 SD = 41 SD = 33.3 SD = 13.0 SD = 81.9 SD = 15.1
Median = 1310 Median = 272 Median = 120.8 Median = 5.6 Median = 80.5 Median = 83.0
Mean = 2621 Mean = 187 Mean = 290.0 Mean = 122.6 Mean = 474.7 Mean = 75.1
SD = 636 SD = 97 SD = 108.6 SD = 42.2 SD = 180.8 SD = 15.9
Median = 2580 Median = 155 Median = 285.6 Median = 110.8 Median = 486.7 Median = 76.2
500 to 2000 200 to 1000 20 to 90 4 to 27 62 to 482 80 to 140
Abbreviations are: PGE2, Prostaglandin E2; PGE-M, 7a-hydroxy-5, I 1-diketotetranorprostane-1 ,16 dioic acid (major urinary metabolite of
systemic E-prostaglandins); THP, Tamm-Horsfall protein; Car, creatinine clearance; ND, not determined.
Table lb. Laboratory parameters from patients with classical Bartter's syndrome
Age Urinary THP Diuresis Urinary Ca
Patients Sex years months Medication Polyhydramnion mg/24 hr/I .73 m2 ml/24 hr Mmoii24 hr/kg
BS 1 male 0.3/12 no no 47.33 405 13.7
BS 2 male 5.3/12 no no 51.23 360 20.6
BS 3 male 17.6/12 no no 23.30 1550 42.3
BS 4 male 15.4/12 no no 26.62 1380 35.1
BS 5 male 14.7/12 no no 17.35 2640 53.2
BS 6 female 12. 1/12 no no 18.75 1030 78.0
Mean = 10.10/12 Mean = 30.76 Mean = 1228 Mean = 40.5
SD = 6.1/12 SD = 13.48 SD = 774 SD = 21.3
Median = 13.4/12 Median = 24.96 Median = 1205 Median = 38.7
Normal range 50 to 100 500 to 2000 20 to 90
Canada; 0.5 ttgiml bicarbonate buffer, pH = 9.4), a second
biotinylated antibody (polyclonal rabbit-anti-human-THP anti-
body, Behring, Marburg, Germany; 2 c.tg/ml PBST, pH = 7.4)
and a streptavidin-peroxidase detection system (Amersham;
dilution 0.5 .d/ml PBST). Microtiter plates (96 wells) were from
NUNC (Wiesbaden, Germany). Sensitivity of the test was
sufficient to allow for strong dilutions of the urine probes in
water. Dilution of the samples was considered an essential step
for disaggregation of clots of THP polymers [22]. Serial dilu-
tions from 1/12.5 to 1/100 in distilled water were chosen
depending on the amount of diuresis of each individual. Purified
human THP was used to establish a standard curve ranging
between 2.35 and 300 nglml. The curve demonstrated a sensi-
tivity of the test down to a concentration of 9.4 ng/ml and
linearity between 70 and 300 ng/ml. Urine samples were frozen
and diluted with distilled water just prior to assay. Standard
THP and samples were further double-diluted in PBST in order
to verify parallelism with the standard curve. In samples with
very low THP concentrations (<70 ng/ml) parallelism of the
dilutions to dilutions of the standard could not be established;
therefore, THP values in these samples were estimated. Inter-
test variability was usually below 15%, intra-test variability was
below 5% (P < 0.05).
Evaluation of other urinary parameters
Excretion rates of PGE2 and PGE-M (7a-hydroxy-5, 11-dike-
totetranorprostane- 1,1 6-dioic acid) were determined as de-
scribed previously [23, 24]. Excretion rates of PGE2 were
thought to reflect renal, and PGE-M to reflect total body
prostaglandin production [25]. Urine osmolality was deter-
mined using a freezing point depression osmometer. For the
determination of urine electrolytes and creatinine, routine lab-
oratory methods were adopted.
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Table ic. Laboratory parameters from healthy controls
Control Sex
Age
years months Medication
Urinary THP
mg/24 hr/1.73 m2
Diuresis
ml/24 hr
Osmolality
mOsmo!/kg
Urinary Ca
pinol/24 hr/kg
Co I
Co 2
Co 3
Co 4
Co 5
Co 6
Co 7
Co 8
Co 9
female
male
male
female
female
female
male
male
female
6. 10/12
9.1/12
8.0/12
7.10/12
4.9/12
10.0/12
0.5/12
3.5/12
4.2/12
no
no
no
no
no
no
no
no
no
41.52
70.01
42.28
45.35
46.10
46.01
85.40
58.51
51.32
590
1200
760
430
700
345
495
405
390
593
210
324
1009
531
1030
740
764
835
29.2
12.6
23.1
60,0
74.1
34.5
90.2
84.1
29.7
Mean = 6.1/12
SD = 2.11/12
Median 6.10/12
Mean = 54.15
SD = 13.91
Median = 46.01
Mean = 591
s = 254
Median = 495
Mean = 671
SD = 267
Median = 740
Mean = 48.6
SD = 27.2
Median = 34.5
Normal range 50 to 100 500 to 2000 200 to 1000 20 to 90
Statistical analysis
For comparison between the groups, the nonparametric
Mann-Whitney test as well as the Wilcoxon signed rank test
were used when appropriate. Where data of the BS group were
included in the statistical evaluations, ANOVA was used.
Differences at a level of P 0.05 were considered significant.
Values of the measurements are given both as means
standard deviation and as medians.
Iintnunohistochemistry on kidney biopsies
For immunohistochemical detection of THP, renal biopsies
(punch biopsies) of the HPS patients number two, four and five
were sectioned in a cryostat microtome. Alternate sections
were used for immunohistochemistry and in situ hybridization
(see below). Treatment of the sections for immunohistochem-
istry included incubation with the same monoclonal anti-THP
antibody used in the ELISA at dilutions of 1/50 and 1/200 in
phosphate buffered saline (PBS) (vol/vol) containing 1% (wt/
vol) of bovine serum albumin and detection of the bound
antibody using a second FITC (fluorescein isothiocyanate)-
labeled antibody at a dilution of 1/40 in bovine serum albumin
(BSA)/PBS (vollvol). Sections were viewed in a Reichert Poly-
var microscope using an HBO 200 watt lamp.
In situ hybridization on kidney biopsies
For in situ hybridization, cryostat sections were mounted on
glass slides coated with poly-L-lysine (Sigma; 100 g/m1 in
bidistilled water). Sections were fixed for 30 minutes in 4%
paraformaldehyde in PBS, pH = 7.4 and stored in 70% ethanol
at 4°C until further use. For hybridization, a 1.98 kb Eco Rl
human kidney uromodulin cDNA fragment obtained by Dr.
Alan Shaw from Glaxo (Geneva, Switzerland) was used. A 665
base pair BamHIfHincII fragment (from position 681 BamHI to
position 1346 HincIl) of the original probe was subcloned into
the BamHI site of the pGEM-4 transcription vector permitting
the generation of sense and antisense riboprobes (R. Metzger,
Heidelberg, Germany). Transcription and hybridization proce-
dures were as described previously [Ii]. Briefly, in vitro tran-
scription of the probes was carried out under incorporation of
t35S]-a-labeled UTP (Dupont NEN; sp. act. 1350 Ci/mmol). For
in situ hybridization, alternate sections were used for sense and
antisense probe hybridization. Activity of the probes used for
hybridization was approximately 3000 and 10000 dpm/d, re-
spectively. Slides were washed in 1 x standard saline citrate
(SSC)/S0% formamide at 48°C for six hours. The washing
solution was changed every 90 minutes. Two final high strin-
gency washes were carried out with either 0.5x or 0.ix SSC,
each for 10 minutes at room temperature. The slides were
dipped in a 50% aqueous solution of photographic emulsion
NTB-2 (Eastman Kodak, Rochester, New York, USA) at 45°C,
exposed at 4°C, developed with D19 developer (Kodak) and
fixed with Unifix (Kodak). The time of exposure of the slides
was either five, 15 or 27 days. Sections were viewed in a
Reichert Polyvar microscope using interference contrast optics.
Results
Urinary parameters
Urinary parameters such as THP excretion, diuresis, osmo-
lality and calcium level are compared between healthy control
children (N = 9, mean age 6.1/12 years) and HPS patients (N =
7, mean age 5.10/12 years) with and without indomethacin
treatment (Table I, Fig. 1). Patients were under constant
indomethacin treatment that was interrupted for a one week's
period in order to establish drug-mediated influences. For
comparison, THP was also determined in the urines from
patients with classical BS (N = 6, mean age 10.10/12 years).
The mean daily THP excretion of the normal control popu-
lation was 54.2 13.9 mg/24 hr corrected to 1.73 m2 body
surface area. The median of these samples was 46.0 mg/24
hr/i .73 m2; the range was between 41.5 and 85.4 mg/24 hr/i .73
m2. HPS patients excreted significantly lower amounts of THP:
after the one week period of omission of indomethacin therapy,
mean THP excretion was i2.7 10.1 mg/24 hr/i .73 m2 (median
7.2, range 2.6 to 30.9 mg/24 hr/l.73 m2). Under indomethacin
treatment, mean THP excretion was even lower than in the
withdrawal period, although the difference was not statistically
significant (10.3 10.1 mg/24 hr/1.73 m2, median 3.5 mg/24
hr/l .73 m2). Mean THP excretion of HPS patients both with and
without indomethacin treatment was significantly different from
controls (P 0.005). For comparison, urine from patients with
BS showed mean THP levels significantly elevated over those
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in HPS patients with or without indomethacin treatment (30.8
13.5 mg/24 hr/l.73 m2, median 25.0, range 17.4 to 51.2 mg/24
hr/i .73 m2; P  0.05). Compared to the control group, THP
levels in BS revealed a weakly significant difference (P =0.45).
HPS patients suffered from massive polyuria (2621 636
ml/24 hr, median = 2580 ml/24 hr), when compared to control
levels (591 254 ml/24 hr, median = 495 ml/24 hr; P  0.005).
This was diminished but not normalized under indomethacin
treatment (1373 529 m1124 hr, median = 1310 ml/24 hr). For
comparison, patients with BS had a moderately enhanced
diuresis with a mean of 1228 774 ml/24 hr, median = 1205
ml/24 hr. During indomethacin withdrawal urine osmolality was
strongly diminished in HPS (187 97 mOsmollkg H20, median
= 155 mOsmollkg H20; P 0.005) suggesting a concentration
defect. Values were improved under indomethacin (268 41
mOsmol/kg H20, median = 272 mOsmollkg H20), but were still
much lower than in controls (671 267 mOsmollkg H20,
median = 740 mOsmol/kg H20; P  0.05). Urinary calcium
excretion was found to reach very high values in HPS patients
during indomethacin withdrawal period (290.0 108.6 smol/24
hr/kg, median = 285.6 ptnol/24 hr/kg; P 0.005). Calciuresis
was improved under indomethacin (110.1 33.3 mo1/24 hr/kg,
median = 120.8 jsmolI24 hr/kg) but was not reset to control
levels (48.6 27.2 jsmolI24 hr/kg, median = 34.5 smo1J24 hr/kg;
P 0.05). There was no correlation between THP levels and
urinary calcium levels either under indomethacin or during the
indomethacin withdrawal period. On X-rays and sonography,
varying extents of bilateral nephrocalcinosis was detected in all
HPS patients. In BS, calcium excretion was within normal
range (40.5 21.3 tmo1I24 hr/kg, median = 38.7 jsmoII24
hr/kg).
Urinary prostaglandin E2 (PGE2) levels were strongly ele-
vated in HPS patients without indomethacin (122.6 42.2
ng/hr/l.73 m2, median = 110.8 ng/hr/1.73 m2) but were within
normal range under indomethacin treatment (10.8 13.0 ng/hr/
1.73 m2, median = 5.6 ng/hr/i.73 m2; P 0.05).
Urinary prostaglandin M (PGE-M) levels, reflecting the sys-
temic prostaglandin synthesis, were elevated in HPS patients
without indomethacin (474.7 180.8 ng/hr/l.73 m2, median =
486.7 ng/hr/l .73 m2) but decreased under indomethacin treat-
ment (114.3 81.9 ng/hr/1.73 m2, median = 80.5 nglhr/1.73 m2;
P 0.05).
Creatinine clearance (Car) in HPS was at the lower margin of
normal (mean 75.1 15.9 ml/min/l.73 m2, median = 76.2
ml/min/1 .73 m2); values were moderately but not significantly
higher under indomethacin (81.9 15.1 mI/mm/i .73 m2, median
= 83.0 ml/min/1.73 m2); Cr was not determined in BS and
controls.
Kidney biopsies
For detection of the THP transcription and translation prod-
uct in renal tissue, biopsies from HPS patients number 2, 4 and
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Fig. 1. Main urinary parameters in healthy controls, in patients with
hyperprostaglandin E-syndrome (HPS) with indo,nethacin treatment
(Indo) and without (no Indo), and in patients with classical Bartter's
syndrome (BS). Bars represent means so. Symbols over "HPS Indo"
and "HPS no Indo" refer to "control"; symbols over "BS" refer to
"HPS no indo." Statistical significance: (*) P  0.005, (+) P 0.05.
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Fig. 2. Immunohistochemistry. Fluorescence photomicrographs of
cryostat sections from renal biopsies stained with anti-THP antibody
(dilution 1/50). FITC-labeled second antibody. Magnification 270 X. a.
Biopsy from patient HPS 5 revealing a longitudinally sectioned cortical
thick ascending limb segment; abnormally weak traces of THP-fluores-
cence are seen in the tubule (arrows). Bright dots indicate hyaline
tubular casts that autofluoresce. b. Biopsy from patient HPS 2 showing
an area of normal-appearing cortical morphology that is deficient of
THP immunoreactivity. c. Specific antibody labeling is focally present
in the biopsy of patient HPS 4. The coexistence of both normal and
reduced THP-immunoreactivity in cortical thick ascending limb profiles
is revealed. d. Biopsy of a normal adult control (unaffected area of a
tumorous adult kidney after interventional nephrectomy) showing a
longitudinally sectioned cortical thick ascending limb segment compa-
rable of the one shown Fig. 2a. Normal THP immunoreactivity is
presented.
5 were investigated using immunohistochemistry with anti-THP
antibody and in situ hybridization with a [35S]-a-labeled UTP
sense and antisense riboprobe, respectively. Immunohis-
tochemically, THP was almost undetectable in the biopsies of
patients HPS 2 and 5 (Fig. 2a,b) but was focally present at
normal strength in the thick ascending limbs in HPS patient 4
(Fig. 2c). For comparison, normal THP immunoreactivity from
intact human renal tissue is shown in Figure 2d. These findings
were reflected in the sections treated by in situ hybridization;
no THP mRNA was detected in biopsies from patients two and
five (Fig. 3a), whereas in patient HPS 4, a focally weak
expression of THP mRNA was found (Fig. 3b). Again for
comparison, normal THP mRNA expression is shown in thick
ascending limb segments from the cortex of an intact adult
human kidney revealing a stronger signal than that in patient
HPS 4 (Fig. 3c). Duration of exposure was the same in all
specimens shown. Presence of thick ascending limb segments in
all three biopsies was carefully controlled by counterstaining
with hematoxylin-eosin, which allowed the identification of
cortical medullary rays containing the straight parts of the
nephrons. In the healthy kidney, thick ascending limb segments
of the medullary rays revealed the strongest THP mRNA-
expression [11]. Figure 4 shows a representative overview of a
histologically stained, THP-negative biopsy (patient HPS 5) to
demonstrate that the majority of nephrons in the biopsies was
histologically intact. However, this observation does not ex-
clude that interstitial calcifications and abnormalities at the
cellular level may exist.
Discussion
The present data provide evidence for markedly reduced
urinary production of Tamm-Horsfall protein in seven infant
patients with hyperprostaglandin E-syndrome as assessed by a
newly adapted ELISA. So far, this is the first study to report a
significantly lowered THP production that is not simply caused
by a reduction of the number of functioning nephrons. Patients
with HPS revealed a moderately reduced creatinine clearance
(median 83.0 mi/minI! .73 m2 under indomethacin treatment),
however, this degree of reduction is not likely to account for the
drastic fall in THP production reaching median values between
one-tenth and one-twentieth of control THP levels. Generally,
urine THP levels are known to be proportionately diminished
with reduced GFR [8]. On the other hand, however, in adult
patients with reduced kidney function, urinary THP levels were
measured that were markedly higher than in HPS despite a
Fig. 3. In situ hybridization. Photomicrographs of cryostat sections
from renal biopsies hybridized with [355]-labeled uromodulin antisense
RNA coding for THP (0.05 ng per section). Fifteen day exposure to film
emulsion. Magnification 330 x. a. No hybridization signal is seen in the
biopsy of patient HPS 2. b. Cortical thick ascending limb segments
(broken lines) of a medullary ray in the biopsy of patient HPS 4 reveal
moderate THP mRNA expression. c. Renal biopsy of a healthy subject
showing strong THP mRNA expression over thick ascending limb
profiles.
median creatinine clearance as low as 26 mi/mm [81. In this
respect, Grant and coworkers [26] stated that in patients with
renal impairment, there was no reduction in THP excretion per
unit of functioning nephron. Thus, HPS apparently represents
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Fig. 4. Photomicro graph of a histologically
stained ctyostat section from a biopsy of
patient HPS 5 revealing interstitial infiltrates
in some areas but normal tubular morphology
in the majority of nephrons of the renal cortex.
Hematoxylin-eosin. Magnification 114 x.
an exception regarding the unproportionately low THP produc-
tion that is paralleled by only moderate reduction in OFR.
In order to demonstrate that the low THP levels in HPS
patients were not due to false determination by ELISA, three
points should be raised. Firstly, problems in the immunological
quantification of THP may stem from the specific physico-
chemical nature of the molecule which tends to form large
aggregated polymers that may reduce antibody detection.
Therefore, we had to dilute urine samples to a high degree, a
step that leads to disaggregation of the glycoprotein [22].
Secondly, structural alterations of THP were reported in vari-
ous disease states including disorders of calcium metabolism
[19, 20] that may alter the conditions of THP determination.
Accordingly, it may be argued that molecular alterations of
THP in HPS may have led to the low urinary THP values
determined. However, using the standard salt precipitation
technique (0.58 M NaC1) originally applied by Tamm and
Horsfall (1950) [21] to isolate a crude THP fraction from urine,
we found that very little THP precipitate was obtained from
HPS urines as compared to controls (Greven, unpublished
observation). Thirdly, the biopsies analyzed for THP expres-
sion by in situ hybridization and immunohistochemistry re-
vealed an almost complete absence of THP transcription and
translation product at the site of THP production, that is, the
thick ascending limb of the loop of Henle. Thus, we may
conclude that HPS is associated with a defect of THP synthesis
at the most proximal level of its mRNA transcription. These
points taken together, we assume that the THP excretions
measured by ELISA reflect an essential defect in THP synthe-
sis in HPS.
Regarding a possible link between the lack of THP and an
impairment in thick ascending limb function, a relationship
between the Na, K, Cl-cotransporter located in this segment
and THP has previously been discussed basing on interactions
of the glycoprotein with loop diuretics [14, 15, 271. However,
other epithelia that possess the Na, K, Cl-cotransporter do not
express THP [28]. On the other hand, the deficiency of the
glycoprotein as a cell coat might affect the maintenance of water
tightness of the thick ascending limb [9], thus leading to an
insufficient medullary concentration gradient. Lack of the cell
coat may as well interfere with the segment's capacity for solute
absorption by influencing the lumen-positive electrochemical
gradient which constitutes the driving force for solute absorp-
tion in the thick ascending limb [29].
A defect in sodium and chloride reabsorption in the thick
ascending limb has been considered a "proximate cause" [2,
30, 31] in Bartter's syndrome and related disorders. The striking
resemblance of HPS symptoms with those resulting from
chronic furosemide treatment, points to an impairment of thick
ascending limb function. Patients under chronic furosemide
therapy reveal all typical symptoms of BS including impalrment
of distal sodium and chloride reabsorption and severe hypokal-
emia [2, 32, 33], increased levels of prostaglandin B2 [34] as well
as hypercalciuria [33, 35], the latter being characteristic for
HPS. Particularly, premature infants receiving furosemide de-
veloped renal medullary calcifications [7]. Thus, it appears as if
in HPS a maximally stimulated "endogenous furosemide-like
loop diuretic" would be active that points to the thick ascending
limb as the crucial source of the disorder. Interestingly, a
remarkable resistance to furosemide therapy has recently been
observed in children with HPS (Seyberth, unpublished obser-
vation).
Whether the lack of THP production represents a primary
defect or whether it is merely a consequence of altered tubular
electrolyte transport or of deteriorated tubular structure, re-
mains to be discussed. A previous study has shown that in rats,
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THP urinary production appears to be constitutive in nature, as
THP levels revealed no or only inconspicuous changes in
different physiological and pathophysiological conditions alter-
ing the transport activity of the thick ascending limb [16, 36].
These findings were paralleled by a study in humans where
different states of diuresis were not accompanied by significant
changes in THP urinary excretion [37]. Therefore, altered
electrolyte transport conditions are not likely to be responsible
for suppressed THP in HPS.
On the other hand, the early onset of an altered calcium
metabolism, which is known to cause cell injury [38], may be
responsible for a tubular defect. Since focal tubular and inter-
stitial fibrosis as well as tubular atrophy were described in
selected biopsies from HPS patients [5], these damages together
with varying extents of nephrocalcinosis may influence both
solute reabsorption and THP production. But since overall
renal structure of our biopsy material was not significantly
deteriorated and accordingly, creatinine clearance of the HPS
patients was at the lower normal range, THP underproduction
is not likely to be derived from renal structural damage.
Related to renal concentrating defect and nephrocalcinosis,
children with classic BS were an appropriate control group.
Urine from BS patients contained significantly higher THP
levels than that in HPS patients. Even if both disorders share a
number of basic features, it has been proposed previously
that—based on clinical and pathophysiological differences be-
tween HPS and BS—both syndromes may represent distinct
pathological entities [4, 5, 39]. Regarding thick ascending limb
function, symptoms in either disease differ with respect to distal
chloride reabsorption, which is present in BS but not in HPS
[4], and in severe calcium malabsorption which is observed in
HPS, but not in BS. However, the question whether the cause
for the difference in THP excretion is based on fundamental
differences between HPS and BS in thick ascending limb
damage, cannot be fully answered by the present data. In HPS,
a primary disorder of the thick ascending limb may cause the
observed lack in THP production which is possibly related to
the early onset of HPS symptoms in intrauterine life. In BS,
where the onset of the disorder normally occurs later in
childhood or in adulthood, abnormal renal growth and devel-
opment is less likely to occur, and damage to the thick ascend-
ing limb may not be of comparable extent. Phenomenologically,
however, the difference in THP urinary excretion supports the
concept that BS and HPS represent two different pathological
entities.
The reason why THP excretion in patients with Bartter's
syndrome was somewhat lower than in controls (statistical
significance P = 0.045), is not clear. Creatinine clearance levels
were not available from these patients and thus, the degree of a
possible structural degradation of the kidney could not be
determined. However, former salt precipitation experiments
have revealed that BS patients excrete rather normal THP
levels (Greven, unpublished observations). Low THP levels in
some of the BS patients may also stem from possible sampling
errors, as urine collections from BS patients came from various
different places and were not as closely monitored as those from
HPS patients.
The primary defect of HPS cannot be clarified by the present
study. It remains to be determined whether HPS is the conse-
quence of a single tubular disorder, or rather the phenotype of
a variety of tubular defects. The drastically elevated renal and
systemic prostaglandin (PG) levels in HPS appearing in early
infancy [4] exert a number of complex effects which may
explain the majority of symptoms characteristic for HPS, like
polyuria, isostenuria and impairment of solute handling [4, 40,
41]. However, since indomethacin treatment sufficiently blocks
PG overproduction, it appears likely that the remaining disor-
ders in HPS are PG-independent or at least do not directly
depend on PG's. Thus, the observed deficiency in THP synthe-
sis with or without indomethacin treatment, in concert with
persisting polyuria and renal calcium leak, points to a selective
defect of both the medullary and the cortical thick ascending
limb of Henle's loop.
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